There is no scientific or therapeutic basis to justify any mechanistic linkage between anti-amyloid/tau antibody approaches employed in Alzheimer's disease, and the use of anti-PD-1/PD-L1 antibodies, which represent a completely different mechanism of action of the therapeutic approach. The gene discussed is CD274; the disease is early-onset autosomal dominant Alzheimer disease.